SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending following its Q4 earnings report, where an EPS and revenue beat was overshadowed by cautious subscriber growth guidance and financial implications of the Warner Bros. Discovery acquisition, including a pause in share buybacks. This has ignited a fierce debate among investors, with many seeing the significant price drop as a generational 'buy the dip' opportunity for long-term content expansion, while others voice strong concerns about the deal's debt, halted buybacks, and Netflix's slowing growth in a competitive streaming market.

Brand Engagement Network, Inc. engages in the provision of conversational artificial intelligence assistants with the purpose of transforming engagement and analytics for businesses through security-focused, multimodal communication and human-like artificial intelligence assistants. The firm is also involved in delivering highly personalized, multi-modal artificial intelligence engagement with a focus on industries where there is a massive workforce gap and an opportunity to transform how consumers engage with networks, providers, and brands. The company is founded on March 14, 2024 and is headquartered in Jackson, WY.

Brand Engagement Network Inc

Brand Engagement Network (BNAI) is trending after announcing an AI licensing partnership in Africa, which has ignited intense community discussion about its market potential. Many traders are focused on the stock's low float and high reported borrow fees, speculating on a significant short squeeze, while others express caution regarding its volatility.

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is trending amid intense market focus on an upcoming high-profile address and recent geopolitical rhetoric, particularly concerning Greenland and global trade. The community is sharply divided, with many anticipating a quick market rebound while others brace for further downside, linking market direction to these unfolding events. This dynamic fuels significant volatility as participants actively debate the broader implications for the economy.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

SPDR Gold Shares (GLD) is experiencing an "insane" rally to new all-time highs, fueled by escalating geopolitical tensions, particularly President Trump's tariff threats against Europe concerning Greenland, alongside broader concerns about US debt and dollar debasement. The community is sharply divided, with bulls celebrating significant gains and predicting much higher prices, while bears warn of a "bubble" and anticipate a "violent pullback" once tensions de-escalate. This robust surge highlights gold's role as a primary safe-haven asset amidst global uncertainty and questions surrounding fiat currency stability.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Tau Medical is surging as the community keenly anticipates an imminent PMDA approval in Japan, following groundbreaking pancreatic cancer trial results demonstrating an 81% disease control rate. This pivotal regulatory decision, coupled with FDA module submission and growing institutional interest, underscores the revolutionary potential of their Alpha DaRT technology in oncology, driving widespread bullish sentiment.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending as President Trump's aggressive rhetoric regarding Greenland and potential new tariffs, coupled with concerns over Japan's bond market, fuels a broad market sell-off. The community is sharply divided, with many anticipating further declines and a retest of crucial support levels, while others expect an eventual 'buy the dip' recovery, viewing current fears as an overreaction.

Hycroft Mining Holding Corp. engages in the exploration, mining, and development of gold and silver properties. The company was founded on August 28, 2017 and is headquartered in Winnemucca, NV.

Hycroft Mining Holding Corporation - Ordinary Shares - Class A

Hycroft Mining Holding Corp

Hycroft Mining is trending due to reports of exceptionally high-grade silver drill results across its vast land, significantly boosting optimism for future production. The community is actively discussing continuous insider buying by Eric Sprott and surging precious metal prices as catalysts for substantial upside, while also considering the company's non-producing status and potential for dilution. This confluence of factors, coupled with discussions of a possible short squeeze and growing silver demand, is driving intense conversation around the mining company.

The Kraft Heinz Co. engages in the manufacture and market of food and beverage products. It operates through the North America and International geographical segments. The company was founded on July 2, 2015, and is headquartered in Pittsburgh, PA.

Kraft Heinz Co

Kraft Heinz is trending as a major institutional holder has registered its substantial stake for a potential sale, creating significant market buzz. This move has ignited a sharp debate among investors, with some viewing it as a bearish signal after a period of underperformance, while others see an attractive opportunity in this dividend-yielding consumer staple. The broader context includes anticipation of a planned company separation into distinct entities, which many believe could unlock value despite ongoing competitive pressures in the food sector.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is experiencing heightened volatility and intense discussion, largely influenced by President Trump's remarks at the Davos World Economic Forum and ongoing geopolitical tensions. The community remains deeply divided, with many bears highlighting significant drops and questioning Bitcoin's safe-haven status amidst rising gold prices, while bulls emphasize strong accumulation by institutional players and technical indicators pointing to a potential rebound from leveraged short attacks.

ProShares Trust - ProShares UltraShort Bloomberg Natural Gas -2x Shares

ProShares UltraShort Bloomberg Natural Gas

KOLD is experiencing significant volatility and declines as natural gas futures surge dramatically, driven by widespread "Arctic Blast" weather forecasts across the US. This rapid price action is causing extreme pressure for many traders, leading to discussions of a "widowmaker" market as some cautiously "buy the dip" on KOLD while others are caught in the squeeze.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Short Interest Update

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX - Get Free Report) saw a significant decline in short interest during the month of December. As of December 31st, there was short interest totaling 4,951,552...

Aldeyra Therapeutics (NASDAQ:ALDX) Shares Cross Above Fifty Day Moving Average - Time to Sell?

Aldeyra Therapeutics (NASDAQ:ALDX) Stock Crosses Above 50-Day Moving Average - Here's Why...

Aldeyra Therapeutics (NASDAQ:ALDX) Stock Crosses Above Fifty Day Moving Average - Should You Sell?

Aldeyra Therapeutics (NASDAQ:ALDX) Share Price Crosses Above 50 Day Moving Average - What's Next...

Aldeyra Therapeutics Target of Unusually Large Options Trading (NASDAQ:ALDX)

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX - Get Free Report) saw some unusual options trading activity on Tuesday. Investors bought 12,807 call options on the stock. This is an increase of 1,592...

<ul class="summary-bullets"><li>The FDA delayed its decision on the dry eye drug Reproxalap without raising new issues.</li><li>The FDA pushed the PDUFA deadline to March 16, 2026, after requesting a clinical study report already reviewed under an earlier filing.</li><li>Regulatory progress continued, with the FDA sharing a draft label and outlining next steps.</li></ul>Aldeyra Therapeutics shares jumped on Tuesday, heading for their best day in more than eight months, after the U.S. Food and Drug Administration (FDA) extended its review of the company’s dry eye drug without flagging any new issues.The stock rose 31% to hit $5.22 at the time of writing.<h2 class="st-heading-2">FDA Timeline</h2>Aldeyra Therapeutics said the FDA has pushed back its decision deadline on Reproxalap, the company’s dry eye drug, to March 16, 2026. The deadline, known as the Prescription Drug User Fee Act target action date, had previously been set for Dec. 16.The extension follows a Dec. 12 meeting between the FDA and the company, during which the agency requested submission of a Clinical Study Report for a dry eye disease field trial. Aldeyra said the report was submitted to the NDA on the same day and was classified by the FDA as a major amendment, triggering the three-month extension.<h2 class="st-heading-2">Scope Of The FDA Request</h2>The company said the FDA made no other requests at the December meeting and did not identify any additional issues with the NDA review. The Clinical Study Report had already been reviewed by the FDA under the drug’s Investigational New Drug file.Aldeyra also said safety data from the field trial had been submitted earlier, in August, at the FDA’s request during the NDA review process.The field trial, for which top-line results were announced in May, did not meet its primary endpoint of improving dry eye symptoms compared with a vehicle control. The company said the trial was supportive of the activity of the drug relative to the vehicle and had been discussed with the FDA before the NDA submission.<h2 class="st-heading-2">Labeling Progress&nbsp;</h2>Earlier this month, the FDA shared a draft of the proposed label for the dry eye drug with Aldeyra, and the company said it has submitted a response. According to Aldeyra, the FDA indicated that if no major deficiencies are identified during the extended review period, the agency plans to communicate proposed labeling requests and any anticipated postmarketing requirements by Feb. 16, 2026.Aldeyra said the NDA was originally submitted on June 16, and was accepted for review as a complete class 2 response in July.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for Aldeyra was ‘extremely bullish’ amid ‘extremely high’ message volume.<figure class="image"><img style="aspect-ratio:972/136;" src="https://news.stocktwits-cdn.com/aldx_ss_png_1199f19110.webp" alt="aldx ss.png" width="972" height="136"><figcaption>ALDX sentiment and message volume as of December 16| Source: Stocktwits</figcaption></figure>One bullish user expects the stock to “keep rising during the day.”<stembedurl>https://stocktwits.com/MUBSN/message/639307502</stembedurl>Another user said, “Abbvie buy this bad boy out!”<stembedurl>https://stocktwits.com/GhostLegend/message/639301686</stembedurl><a href="https://stocktwits.com/symbol/ALDX">Aldeyra’s stock</a> has risen 4% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Aldeyra Therapeutics logo is seen displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Why Is Aldeyra Therapeutics Stock Surging After FDA Delayed Its Dry Eye Drug Decision?

The FDA delayed its decision on the dry eye drug Reproxalap to March 2026 without raising new issues, while review and labeling discussions continued.

Equity

683 Capital Management LLC Has $4.14 Million Stake in Aldeyra Therapeutics, Inc. $ALDX

683 Capital Management LLC grew its position in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX - Free Report) by 126.9% during the second quarter, according to the company in its most recent 13F filing with...

Aldeyra Therapeutics, Inc. $ALDX Shares Sold by Kennedy Capital Management LLC

Kennedy Capital Management LLC lessened its position in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX - Free Report) by 44.3% in the second quarter, according to the company in its most recent Form 13F...

Kennondale Capital Management LLC Sells 94,551 Shares of Aldeyra Therapeutics, Inc. $ALDX

Kennondale Capital Management LLC trimmed its holdings in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX - Free Report) by 62.5% in the second quarter, according to its most recent disclosure with the...

Savant Capital LLC Makes New $552,000 Investment in Aldeyra Therapeutics, Inc. $ALDX

Savant Capital LLC bought a new position in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX - Free Report) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission...

Aldeyra Therapeutics Announces Expansion of RASP Platform to Include Central Nervous System Diseases and Provides Updates on Reproxalap at Research & Development Webcast

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced at...

Aldeyra Therapeutics, Inc. is a biotechnology company, which engages in research and development activities with related general business planning, including raising capital. It engages in the discovery of therapies designed to treat immune-mediated diseases. The company was founded by Thomas A. Jordan and John E. Dowling on August 13, 2004 and is headquartered in Lexington, MA.

Aldeyra Therapeutics Inc

Up 10% or more

0% to up 9%

Down 1% to 9%

Down 10% or more

The S&P 500 enters 2026 after a strong run. What kind of return do you expect this year?

How will the S&amp;P 500 perform in 2026?

Current Price	$4.75
Prev Close	$4.63
Open	$4.52
Dividend Yield	0.00%
50-Day Moving Average	$4.85
Beta	2.77
Avg. Volume	1.51M
PE Ratio	-6.58

52-Week High	$7.20
52-Week Low	$1.14
Market Capitalization	$278.55M
EPS (Annual)	-$0.9389
Price to Book	5.80
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

ALDX
Aldeyra Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ALDX News

ALDXAldeyra Therapeutics Inc